The sale is a win for Bristol-Myers Squibb, which is working to overcome antitrust concerns to secure approval for its $74 billion acquisition of Celgene.
Bristol-Myers said in June it would sell Otezla to ease concerns raised by the Federal Trade Commission because of a competing treatment it is developing.
Otezla had $1.61 billion in sales last year. Amgen expects sales from the drug to increase over the next five years.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
